Researchers at Fred Hutch Cancer Center invented a new screening method called ReLiC that uses CRISPR-Cas9 to test all the ...

A study published in Nature shows that certain autoantibodies may influence how cancer patients respond to immunotherapy. Autoantibodies are proteins produced by the immune system and have typically ...

Ten Washington state health organizations recently received grants of up to $15,000 from Fred Hutch Cancer Center’s Community ...

At first glance, art and science might seem like opposite worlds — one driven by imagination and emotion, the other by data ...

Dr. Folashade Otegbeye, facility director of the Therapeutic Products Program at Fred Hutch, works to rapidly translate what ...

In 2024, Obliteride raised more than $9 million for research at Fred Hutch, contributing to more than $58 million raised since 2013. These funds have fueled urgently needed advances in cancer ...

A study from Fred Hutch Cancer Center finds that some cancer patients' antibodies can boost their response to immunotherapy treatment.

Fred Hutch's mission is the elimination of cancer and related diseases as causes of human suffering and death through prevention and curative treatments accessible to all patients.

Blood clots can be a common – and even deadly – side effect of both cancer and its treatment. Fred Hutch's Dr. Gary Lyman, an expert in blood clots (also known as thrombi) is helping set national ...

In just 50 years, Fred Hutch grew from a regional cancer center into a world-class biomedical research and clinical care institution known for its expertise in molecular biology, tumor virology and ...